<DOC>
	<DOCNO>NCT01527279</DOCNO>
	<brief_summary>The purpose randomize , double blind , placebo-controlled , superiority clinical trial ass clinical efficacy antazoline rapid conversion atrial fibrillation observation sinus rhythm .</brief_summary>
	<brief_title>Antazoline Rapid Cardioversion Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>Antazoline first generation antihistaminic agent chinidin-like property . When administer intravenously , antazoline exerts strong antiarrhythmic effect supraventricular arrhythmia especially atrial fibrillation ( AF ) facilitate rapid conversion sinus rhythm . Despite relative lack publish data antazoline market Poland widely use cardiology ward emergency room due efficacy , safety rapid onset action within minute administration . To show superiority antazoline placebo sample size 80 patient calculate base follow assumption : two-tailed test , type I error 0.01 , power 90 % , efficacy placebo 5 % , efficacy antazoline 50 % 20 % drop-out rate fulfill criterion intention-to-treat analysis . Due presume lack statistical power secondary end point safety endpoint consider exploratory .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Antazoline</mesh_term>
	<criteria>Written inform consent participate study write standard version inform consent cardioversion accept Institute Cardiology , Warsaw , Poland Age 18 good general condition Potassium level 3.5 mmol/l Stable cardiopulmonary state enrollment In case unclear history heart failure suspicion impair left ventricle function echocardiography indicate prior enrollment A longterm antiarrhythmic drug therapy allow Lack write informed consent Antazoline allergy AF relate significant valvular disease Clinically significant heart failure ejection fraction &lt; 55 % Diastolic blood pressure ( BP ) &lt; 100mmHg History significant bradyarrhythmia treat permanent pacemaker QT prolongation 440ms QTc ( Bazett 's formula ) population norm Tachycardia &gt; 160 ' Advanced liver kidney failure Acute coronary syndrome , coronary artery bypass graft , stroke transient ischemic attack within 30 day enrollment Preexcitation ECG treat radiofrequency ablation accessory pathway Signs symptom ischemia relate AF An investigational drug use within 30 day enrollment Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>paroxysmal</keyword>
	<keyword>cardioversion</keyword>
	<keyword>antazoline</keyword>
</DOC>